(Q24234378)

23 October 2023

Richard L Nelson

1

Richard L

Nelson

1 reference

23 October 2023

Philippa Kelsey

2

Philippa

Kelsey

1 reference

23 October 2023

Hayley Leeman

3

Hayley

Leeman

1 reference

23 October 2023

Naomi Meardon

4

Naomi

Meardon

1 reference

23 October 2023

Haymesh Patel

5

Haymesh

Patel

1 reference

23 October 2023

Kim Paul

6

Kim

Paul

1 reference

23 October 2023

Ben Taylor

8

Ben

Taylor

1 reference

23 October 2023

Elizabeth Wood

9

Elizabeth

Wood

1 reference

23 October 2023

Rexanna Malakun

10

Rexanna

Malakun

1 reference

Cochrane Database of Systematic Reviews

23 October 2023

language of work or name

English

0 references

publication date

7 September 2011

0 references

published in

0 references

issue

9

0 references

page(s)

CD004610

0 references

cites work

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Subgroup analysis and other (mis)uses of baseline data in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Diagnosis and treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

A review of mortality due to Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Quebec to report on Clostridium difficile in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Clinical and laboratory observations in Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Clostridium difficile: clinical considerations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004610.PUB4

7 January 2021

10.1002/14651858.CD004610.PUB4

Identifiers

DOI

0 references

Fatcat ID

release_vgoitybuaretbfngwc3tne7pcm

0 references